The United Kingdom and the United States have agreed to a key trade agreement that will maintain zero tariffs on British drug products being sold in the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to increase funding on drugs through the National Health Service (NHS). This pledge ensures that tariffs on these vital goods will remain at zero for a period of three years.
This development follows previous warnings to hike duties on patented drug products, with potential rates floated as high as one hundred percent.
"This arrangement with the United Kingdom bolsters the global environment for cutting-edge drugs and introduces long-overdue fairness to U.S.–U.K. drug exports," a statement declared.
Commercial Significance
Drugs are one of the UK's largest exports to the America, which is clearly the primary destination for leading companies like GSK and AstraZeneca.
Trade data reveal that in the 12 months prior to the third quarter, the UK exported drugs worth over eleven billion pounds to the US. This value made up a significant portion of all goods exports in that span.
"This guarantee safeguards jobs, boosts capital expenditure and sets the stage for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Key NHS Changes
The agreement involves several specific changes from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new therapies to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to increase total public funding on treatments from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The sum drug companies must pay back to the NHS to control costs will be limited at 15%. In the past, refunds were more than 20%.
Industry Background
The deal comes amid a long-running row between the drug companies and the ministers over drug pricing and regulatory access.
This friction were heightened by arguments that American patients were charged a premium for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been announced toward US facilities.
One official stated that the NHS had to invest a greater share on drugs, noting that its budget allocation on drugs had declined as a percentage of its resources over the past decade.
